ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter

Japan delays approval of first domestic oral COVID-19 drug

Expert panel wants more data; Shionogi stock sinks 8.5% in Tokyo trade

Shionogi had filed for approval of its oral COVID-19 drug Xocova, with the health ministry in February, but a decision has been delayed. (Source photo by Yo Inoue and courtesy of the company)

TOKYO (Reuters) -- Shares in Shionogi & Co posted their steepest fall in three months on Thursday after a health ministry panel again delayed emergency approval for the Japanese drugmaker's oral treatment against COVID-19.

The stock dropped 8.5% to 6,901 yen as of 10:22 JST, the most since April 13, leading decliners on the benchmark Nikkei index, which was down 0.4%.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more